Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beclomethasone dipropionate + salbutamol is a fixed-dose combination inhaler containing two active ingredients used primarily for the treatment and management of asthma and chronic obstructive pulmonary disease (COPD). Salbutamol (also known as albuterol) is a short-acting beta2 adrenergic receptor agonist that acts as a bronchodilator, relaxing airway smooth muscle to rapidly relieve bronchospasm. Beclomethasone dipropionate is an inhaled corticosteroid that reduces inflammation in the airways by inhibiting the release of pro-inflammatory mediators. The combination provides both rapid symptom relief (via salbutamol) and long-term control of airway inflammation (via beclomethasone), making it suitable for maintenance therapy in patients with asthma or COPD who require both components[1][6][2]. This medication is typically administered via metered dose inhaler.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclomethasone dipropionate + salbutamol.